Patents by Inventor Reid M. Rubsamen
Reid M. Rubsamen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210292406Abstract: An injectable formulation, comprising: poly(lactic-co-glycolic (PLGA) microsphere encapsulating siltuximab, wherein microspheres are sized to release siltuximab over a period of hours, days and weeks, where the biocompatible polymer releases antibody at an absorption rate which is characterized by an absorption rate constant (Ka (h?1) in the range of (0.001 to 2.048)+/?20%, or +/?10%, or +/?5%. for use and treating human patients with infections. The invention includes treating patients with viral infections of SARS-Cov-2 using siltuximab.Type: ApplicationFiled: March 16, 2021Publication date: September 23, 2021Applicant: Flow Pharma, Inc.Inventors: Reid M. Rubsamen, Scott Burkholtz, Charles V. Herst, Tom Hodge, Lu Wang
-
Publication number: 20200276288Abstract: A method of making a personalized cancer vaccine is disclosed. The method includes predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. The predicting step can be implemented using artificial intelligence, statistical modeling, or a combination thereof. Particles are created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a biocompatible material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.Type: ApplicationFiled: March 2, 2020Publication date: September 3, 2020Applicant: FLOW PHARMA, INC.Inventors: REID M. RUBSAMEN, CHARLES V. HERST, LU WANG, SCOTT R. BURKHOLZ, RICHARD T. CARBACK, III, SERBAN I. CIOTOS
-
Publication number: 20200276289Abstract: A personalized cancer vaccine is disclosed. The vaccine is comprised of particles encapsulating neoantigens. The neoantigens are chosen by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and using the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.Type: ApplicationFiled: March 2, 2020Publication date: September 3, 2020Applicant: FLOW PHARMA, INC.Inventors: REID M. RUBSAMEN, CHARLES V. HERST, LU WANG, SCOTT R. BURKHOLZ, RICHARD T. CARBACK, III, SERBAN I. CIOTIOS
-
Publication number: 20190105387Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: ApplicationFiled: December 11, 2018Publication date: April 11, 2019Applicant: FLOW PHARMA, INC.Inventors: REID M. RUBSAMEN, DAVID EARL HECKERMAN
-
Patent number: 10172936Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: GrantFiled: July 20, 2016Date of Patent: January 8, 2019Assignee: FLOW PHARMA, INC.Inventors: Reid M. Rubsamen, David Earl Heckerman
-
Publication number: 20160324956Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Applicant: FLOW PHARMA, INC.Inventors: REID M. RUBSAMEN, DAVID EARL HECKERMAN
-
Patent number: 9408906Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: GrantFiled: June 6, 2011Date of Patent: August 9, 2016Assignee: FLOW PHARMA, INC.Inventors: Reid M. Rubsamen, David Earl Heckerman
-
Publication number: 20160154946Abstract: A computer system for obtaining, analyzing and providing information to a community of user patients regarding their medication is disclosed. The system is provided by means of world wide web access and generates a user patient screen prompting the manual entry of data relating to the use patient and drugs being taken. The data are analyzed and results are provided to the user patient and/or the caregiver including drug-drug interactions, drug pricing, alternative medications and possible adjustments in the dosing regimen of the user patient.Type: ApplicationFiled: February 3, 2016Publication date: June 2, 2016Inventor: Reid M. RUBSAMEN
-
Publication number: 20150132398Abstract: A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell.Type: ApplicationFiled: January 21, 2015Publication date: May 14, 2015Applicant: FLOW PHARMA, INC.Inventors: CHARLES VINCENT TAYLOR HERST, REID M. RUBSAMEN
-
Publication number: 20140105970Abstract: A composition as disclosed is comprised of a plurality of particles and a pharmaceutically acceptable carrier. The particles are comprised of (1) an adjuvant; (2) a biocompatible polymer which maybe a co-polymer such as PLGA, and (3) a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. The carrier includes an adjuvant such as a monophosphoryl lipid A (MPL) different from the adjuvant in the particles. The particles may be sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Inventors: REID M. RUBSAMEN, CHARLES VINCENT TAYLOR HERST, DAVID EARL HECKERMAN
-
Publication number: 20120231044Abstract: A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell.Type: ApplicationFiled: March 12, 2012Publication date: September 13, 2012Inventors: Charles Vincent Taylor Herst, Reid M. Rubsamen
-
Patent number: 8138157Abstract: A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.Type: GrantFiled: April 12, 2010Date of Patent: March 20, 2012Assignee: Flow Pharma, Inc.Inventor: Reid M. Rubsamen
-
Publication number: 20110300226Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: ApplicationFiled: June 6, 2011Publication date: December 8, 2011Inventors: Reid M. RUBSAMEN, David Earl Heckerman
-
Publication number: 20100291220Abstract: A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.Type: ApplicationFiled: April 12, 2010Publication date: November 18, 2010Inventor: REID M. RUBSAMEN
-
Publication number: 20100285137Abstract: A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.Type: ApplicationFiled: April 12, 2010Publication date: November 11, 2010Inventor: REID M. RUBSAMEN
-
Patent number: 7490603Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.Type: GrantFiled: November 21, 2005Date of Patent: February 17, 2009Assignee: Aradigm CorporationInventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
-
Patent number: 7448375Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.Type: GrantFiled: May 17, 2005Date of Patent: November 11, 2008Assignee: Aradigm CorporationInventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
-
Publication number: 20080264416Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.Type: ApplicationFiled: July 2, 2008Publication date: October 30, 2008Applicant: Novo Nordisk A/SInventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
-
Patent number: 7278419Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering aerosolized insulin. Repeatability of dosing is obtainable by using either regular insulin or monomeric insulin. When delivering insulin (not monomeric) by inhalation, the total inhaled volume should be about the same at each delivery to obtain repeatable results. The patient can be coached (by teaching) to inhale a given amount of air and can also be coached (by teaching) to inhale at a given flow rate. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. A dry powder or a liquid insulin formulation is delivered to the patient from a mechanical or electronic hand-held, self-contained device.Type: GrantFiled: January 30, 2004Date of Patent: October 9, 2007Assignee: Novo Nordisk A/SInventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
-
Patent number: 7258850Abstract: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.Type: GrantFiled: October 14, 2003Date of Patent: August 21, 2007Assignee: Aradigm CorporationInventors: Reid M. Rubsamen, Robert Cole, James Blanchard, Jeffrey Schuster, Lawrence Linn, John Thipphawong